ArticleCureus2025
Atypical Presentations of Acyclovir-Resistant Herpes Simplex Virus in Immunocompromised Patients: A Case Series.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herpes simplex virus (HSV) infections in immunocompromised patients can have atypical presentations - anywhere from granulomatous to linear erosive lesions - and become refractory to standard therapy. We report three cases of necrotizing cutaneous HSV infection in immunocompromised patients with underlying hematologic malignancies or prior chemoradiation, all presenting with atypical and refractory manifestations of the disease. One case involved a 53-year-old female patient with relapsed/refractory acute myeloid leukemia (AML) who developed a necrotizing cutaneous HSV infection refractory to acyclovir and subsequently foscarnet. Two additional cases highlight similar cutaneous presentations of HSV, a patient with anal squamous cell carcinoma and a patient with multiple myeloma, underscoring the variability and severity of the disease in the setting of profound immunosuppression. These cases underscore the possible need for prolonged antiviral therapy, early resistance testing, and adjunctive treatment strategies in managing atypical HSV infections in severely immunocompromised patients. Further studies are needed to establish evidence-based protocols for such challenging cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.